S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.94 (+1.59%)
MSFT   318.85 (+0.98%)
META   306.90 (+2.23%)
GOOGL   133.50 (+2.02%)
AMZN   129.30 (+1.71%)
TSLA   248.81 (-0.56%)
NVDA   447.80 (+2.94%)
NIO   8.85 (-2.10%)
BABA   86.43 (-0.36%)
AMD   103.48 (+0.64%)
T   14.92 (-0.67%)
F   12.41 (-0.08%)
MU   68.95 (+1.35%)
CGC   0.79 (+0.64%)
GE   110.22 (-0.30%)
DIS   81.18 (+0.16%)
AMC   8.23 (+3.00%)
PFE   33.45 (+0.84%)
PYPL   59.62 (+1.98%)
NFLX   382.08 (+1.19%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.94 (+1.59%)
MSFT   318.85 (+0.98%)
META   306.90 (+2.23%)
GOOGL   133.50 (+2.02%)
AMZN   129.30 (+1.71%)
TSLA   248.81 (-0.56%)
NVDA   447.80 (+2.94%)
NIO   8.85 (-2.10%)
BABA   86.43 (-0.36%)
AMD   103.48 (+0.64%)
T   14.92 (-0.67%)
F   12.41 (-0.08%)
MU   68.95 (+1.35%)
CGC   0.79 (+0.64%)
GE   110.22 (-0.30%)
DIS   81.18 (+0.16%)
AMC   8.23 (+3.00%)
PFE   33.45 (+0.84%)
PYPL   59.62 (+1.98%)
NFLX   382.08 (+1.19%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.94 (+1.59%)
MSFT   318.85 (+0.98%)
META   306.90 (+2.23%)
GOOGL   133.50 (+2.02%)
AMZN   129.30 (+1.71%)
TSLA   248.81 (-0.56%)
NVDA   447.80 (+2.94%)
NIO   8.85 (-2.10%)
BABA   86.43 (-0.36%)
AMD   103.48 (+0.64%)
T   14.92 (-0.67%)
F   12.41 (-0.08%)
MU   68.95 (+1.35%)
CGC   0.79 (+0.64%)
GE   110.22 (-0.30%)
DIS   81.18 (+0.16%)
AMC   8.23 (+3.00%)
PFE   33.45 (+0.84%)
PYPL   59.62 (+1.98%)
NFLX   382.08 (+1.19%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.94 (+1.59%)
MSFT   318.85 (+0.98%)
META   306.90 (+2.23%)
GOOGL   133.50 (+2.02%)
AMZN   129.30 (+1.71%)
TSLA   248.81 (-0.56%)
NVDA   447.80 (+2.94%)
NIO   8.85 (-2.10%)
BABA   86.43 (-0.36%)
AMD   103.48 (+0.64%)
T   14.92 (-0.67%)
F   12.41 (-0.08%)
MU   68.95 (+1.35%)
CGC   0.79 (+0.64%)
GE   110.22 (-0.30%)
DIS   81.18 (+0.16%)
AMC   8.23 (+3.00%)
PFE   33.45 (+0.84%)
PYPL   59.62 (+1.98%)
NFLX   382.08 (+1.19%)
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Forecast, Price & News

$1.30
0.00 (0.00%)
(As of 09/29/2023 08:54 PM ET)
Compare
Today's Range
$1.30
$1.34
50-Day Range
$0.55
$2.60
52-Week Range
$0.48
$10.80
Volume
600 shs
Average Volume
1,587 shs
Market Capitalization
$4.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ARTH stock logo

About Arch Therapeutics (OTCMKTS:ARTH) Stock

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

ARTH Price History

ARTH Stock News Headlines

Arch Therapeutics Provides AC5® Commercialization Update
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Dr. Arth Patel
Double Arch
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Arch Therapeutics Inc (ARTHD)
ARTH Arch Therapeutics, Inc.
See More Headlines
Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Company Calendar

Last Earnings
8/11/2023
Today
10/02/2023
Next Earnings (Estimated)
12/25/2023
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-5,280,000.00
Net Margins
-16,959.23%
Pretax Margin
-16,956.59%

Debt

Sales & Book Value

Annual Sales
$20,000.00
Book Value
($3.36) per share

Miscellaneous

Free Float
2,955,000
Market Cap
$4.02 million
Optionable
Not Optionable
Beta
0.65
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Terrence W. Norchi M.D. (Age 58)
    Co-Founder, Chairman, Pres & CEO
    Comp: $450.5k
  • Mr. Michael S. Abrams (Age 53)
    CFO & Treasurer
    Comp: $325k
  • Mr. Daniel M. Yrigoyen (Age 53)
    VP of Sales
    Comp: $316.67k
  • Dr. Rutledge Ellis-Behnke Ph.D.
    Co-Founder & Scientific Advisor













ARTH Stock - Frequently Asked Questions

How have ARTH shares performed in 2023?

Arch Therapeutics' stock was trading at $0.0260 at the beginning of 2023. Since then, ARTH stock has increased by 4,900.0% and is now trading at $1.30.
View the best growth stocks for 2023 here
.

Are investors shorting Arch Therapeutics?

Arch Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 3,700 shares, an increase of 76.2% from the August 31st total of 2,100 shares. Based on an average daily trading volume, of 14,500 shares, the short-interest ratio is presently 0.3 days.
View Arch Therapeutics' Short Interest
.

When is Arch Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, December 25th 2023.
View our ARTH earnings forecast
.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) announced its quarterly earnings data on Friday, August, 11th. The biotechnology company reported ($1.42) earnings per share (EPS) for the quarter. The biotechnology company earned $0.01 million during the quarter.

What other stocks do shareholders of Arch Therapeutics own?
What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $1.30.

How much money does Arch Therapeutics make?

Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $4.02 million and generates $20,000.00 in revenue each year.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The official website for the company is www.archtherapeutics.com. The biotechnology company can be reached via phone at (617) 431-2313 or via email at investors@archtherapeutics.com.

This page (OTCMKTS:ARTH) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -